Biomedical Advanced Research and Development Authority (BARDA)

Vaxxas is a biotechnology company based in Brisbane, Australia, focused on developing a novel needle-free vaccination technology. Established in 2011, Vaxxas employs proprietary dry-coating technology that significantly reduces or eliminates the need for refrigeration during the storage and transportation of vaccines, thereby addressing logistical challenges associated with the cold chain. The company's innovative delivery system features an array of vaccine-coated micro projections that penetrate the outer layers of the skin when applied with a specialized applicator device. This method allows for the direct deposition of vaccines among a dense population of immune cells in the skin, potentially transforming the global delivery of vaccines.

Eradivir is a biotechnology company founded in 2020 and headquartered in West Lafayette, Indiana. The company specializes in developing a novel bispecific immunotherapy platform aimed at combating viruses, particularly the one responsible for COVID-19. Eradivir’s unique approach involves creating non-immunological targeting agents that attach with high specificity to a distinct domain of the spike protein present on various coronaviruses. This technology empowers patients' immune systems to effectively eliminate both free viruses and infected cells, even in late-stage infections. Through its innovative research and development efforts, Eradivir seeks to enhance therapeutic options in the fight against viral infections.

Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from acute respiratory and critical care conditions including respiratory depression caused by drug overdose, post-surgery, and pathogens.

Care Access Research provides clinical research and clinical trial services. Care Access Research goal is to engage every healthcare professional in clinical research and to make clinical trials a care option for every patient.

CastleVax operates as a clinical-stage vaccine research company. CastleVax is reimagining how to provide safe and effective vaccines for all humans, everywhere.

Walgreens is the largest drugstore chain in the United States, operating 7,689 locations across all 50 states, the District of Columbia, and Puerto Rico. The company serves nearly 6 million customers daily, offering convenient access to a wide range of consumer goods, pharmacy services, and health and wellness solutions. Walgreens provides various pharmacy services, including retail, specialty, infusion, medical facility, and mail services, alongside respiratory care. These services aim to enhance health outcomes while reducing costs for various stakeholders, including employers and managed care organizations. A subsidiary of Walgreens, Take Care Health Systems, manages over 700 worksite health centers and in-store clinics, further expanding the company's reach in providing accessible healthcare solutions.

Qpex Biopharma is a San Diego-based biopharmaceutical company founded in 2018, focused on developing innovative therapies to address the growing challenge of antimicrobial resistance. The company specializes in creating a pipeline of antibiotic drugs aimed at treating infectious diseases in both inpatient and outpatient settings. With a strong emphasis on the discovery, development, and regulatory approval of anti-infective medicines, Qpex Biopharma leverages its expertise and experience in collaboration with public and private partnerships to meet critical medical needs. The company's mission is to provide effective solutions for healthcare professionals facing the complexities of resistant infections, thereby enhancing treatment options for patients.

ATCC global biological materials resource and standards organization whose mission focuses on the acquisition, authentication, production, preservation, development, and distribution of standard reference microorganisms, cell lines, and other materials. While maintaining traditional collection materials, ATCC develops high-quality products, standards, and services to support scientific research and breakthroughs that improve the health of global populations.

Battelle is the largest independent research and development organization globally, based in Columbus, Ohio. Established in 1929, it operates as a nonprofit private foundation focused on advancing scientific discovery and innovation. Battelle brings together experts in various fields to foster collaboration between people, science, and technology, aiming to accelerate advancements that benefit society. The organization is governed by a board of directors, ensuring that its resources are directed towards impactful research and development initiatives.

Draper is a non-profit laboratory established in 1973, located in Cambridge, Massachusetts, that focuses on applied research, engineering development, education, and technology transfer. The laboratory provides engineering services to governments, industries, and academic institutions, acting as both a prime contractor and subcontractor, while also participating in collaborative consortia. Draper offers impartial assessments of technologies or systems proposed by other organizations. Its areas of specialization include precision instrumentation, fault-tolerant and autonomous systems, image and data analytics, human systems technology, materials engineering and microfabrication, as well as biomedical solutions.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, founded in 2016. It specializes in developing innovative therapeutic products aimed at treating and preventing serious infectious diseases. The company's pipeline includes several promising candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established various collaborations and agreements with notable organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, and Alnylam Pharmaceuticals, among others. Additionally, it has a manufacturing agreement with Samsung Biologics for the production of SARS-CoV-2 antibodies aimed at potential COVID-19 treatment. Through its innovative approaches, Vir Biotechnology aspires to significantly reduce the burden of infectious diseases in the future.

Rivanna Medical, LLC is a medical technology company founded in 2010 and headquartered in Charlottesville, Virginia. The company specializes in the development and commercialization of Accuro, an advanced ultrasound-based system designed to enhance the application of spinal and epidural anesthesia through automated three-dimensional navigation of the lumbar spine. In addition to its primary focus on anesthesia, Rivanna Medical's technology also encompasses various imaging applications, including diagnostic imaging for musculoskeletal and abdominal anatomies. By leveraging innovative ultrasound technology, Rivanna Medical aims to lower healthcare costs, improve patient outcomes, and minimize the risks associated with radiation from traditional X-ray-based imaging.

Aptitude Medical Systems is a biotechnology research company specializing in molecular recognition technology that utilizes aptamers to address the limitations of traditional antibodies. By developing highly stable and resistant aptamers, the company offers solutions that bind with high affinity and specificity to challenging targets, even discriminating between targets that differ by a single functional group. This innovation enables a range of applications across life sciences, diagnostics, and therapeutics, facilitating the creation of advanced products tailored to meet the stringent demands of molecular recognition. Through its partnerships, Aptitude aims to advance the capabilities of molecular diagnostics and therapeutic interventions.

Sabin Vaccine Institute is dedicated to enhancing vaccine accessibility and promoting immunization, particularly in low- and middle-income populations that are most vulnerable to infectious diseases. The organization focuses on the development of innovative vaccines aimed at preventing a wide range of diseases, thereby improving public health outcomes. By striving to make vaccines available globally, Sabin Vaccine Institute seeks to benefit individuals and communities, ultimately contributing to better healthcare and disease prevention efforts worldwide.

OraSure Technologies, Inc. develops, manufactures, and markets oral fluid diagnostic products and specimen collection devices used for detecting critical medical conditions. The company operates primarily in two segments, focusing on a diverse range of products that include rapid tests for HIV, HCV, and Ebola, as well as drug testing and alcohol testing solutions. Notable offerings include the OraQuick Rapid HIV test, the Intercept Oral Fluid Drug Testing System, and the Q.E.D. Saliva Alcohol Test. Additionally, OraSure provides genomic products through its subsidiary, DNA Genotek, which specializes in oral fluid sample collection for molecular diagnostics. The company's products cater to clinical laboratories, hospitals, community organizations, and government agencies, and are available in pharmacies across multiple continents. Founded in 2000 and headquartered in Bethlehem, Pennsylvania, OraSure Technologies is committed to advancing diagnostic solutions and improving public health outcomes.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from acute respiratory and critical care conditions including respiratory depression caused by drug overdose, post-surgery, and pathogens.

Sabin Vaccine Institute is dedicated to enhancing vaccine accessibility and promoting immunization, particularly in low- and middle-income populations that are most vulnerable to infectious diseases. The organization focuses on the development of innovative vaccines aimed at preventing a wide range of diseases, thereby improving public health outcomes. By striving to make vaccines available globally, Sabin Vaccine Institute seeks to benefit individuals and communities, ultimately contributing to better healthcare and disease prevention efforts worldwide.

Arcturus Therapeutics is an RNA medicines company based in San Diego, California, founded in 2013. It specializes in the discovery and development of novel RNA therapeutics aimed at treating rare diseases, particularly in the areas of liver and respiratory care. The company leverages its proprietary Self-Transcribing and Replicating RNA (STARR) technology and Unlocked Nucleic Acid (UNA) chemistry to create RNA drug substances and nanoparticle-formulated products. Arcturus's pipeline includes several preclinical and clinical programs, such as LUNAR-OTC for ornithine transcarbamylase deficiency, LUNAR-CF for cystic fibrosis, and LUNAR-COV19, a vaccine candidate targeting the Coronavirus outbreak. The company holds a robust patent portfolio, encompassing 182 patents and applications globally, enabling it to target any gene in the human genome. Furthermore, Arcturus has established collaborations with various pharmaceutical partners to advance its therapeutic candidates across multiple disease indications.

Spectral AI, Inc. is a predictive analytics company specializing in advanced optical technology and artificial intelligence for wound healing predictions. The company has developed the DeepView® Wound Imaging Solution, a proprietary multispectral imaging system that has received FDA Breakthrough Designation for its application in assessing burn wounds. This innovative technology enables clinicians to differentiate between non-healing and healing human tissue that is typically invisible to the naked eye. By providing 'Day One' healing assessments for conditions such as burn wounds and diabetic foot ulcers, Spectral AI aims to enhance the accuracy and speed of treatment decisions in the wound care sector.

EverGlade Consulting is a national consulting firm that offers management consulting solutions. The firm provides government funding, product development, litigation support, CHIPS funding applications, and DOE Loan Program application support solutions. It helps clients navigate the federal landscape. Its company incorporates market-based analytics based on industry, allowing us to focus more on organizational operations.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Visby Medical, Inc. is a diagnostics company based in San Jose, California, specializing in the development of polymerase chain reaction (PCR)-based diagnostic tests for infectious diseases. Founded in 2008 and formerly known as Click Diagnostics Inc., the company focuses on creating single-use, handheld testing kits that provide instrument-free results for various health conditions, including respiratory infections and sexually transmitted diseases. Visby Medical aims to redefine the testing and treatment of illnesses through a human-centric, technology-driven approach, ensuring that diagnostic tools are not only highly accurate but also user-friendly. The company's services are utilized by governments, national NGOs, and private health providers, reflecting its commitment to making infectious disease testing more accessible and convenient for patients.

The Stevanato Group S.p.A. is a global manufacturer specializing in packaging containers made from glass tubing, specifically for the pharmaceutical industry. The company focuses on providing high-quality solutions that meet the stringent requirements of pharmaceutical packaging. With a commitment to innovation and quality, Stevanato Group serves a worldwide market, catering to the needs of various stakeholders in the pharmaceutical sector.

Opiant Pharmaceuticals, a specialty pharmaceutical company based in Santa Monica, California, focuses on developing medicines to treat addictions and drug overdoses. Founded in 2005, the company has created NARCAN nasal spray, a widely recognized treatment for reversing opioid overdoses. Opiant's pipeline includes potential treatments for alcohol use disorders, acute cannabinoid overdose, and opioid use disorders. The company leverages intranasal and injectable delivery technologies to address these critical health issues.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.

Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.

Spectral AI, Inc. is a predictive analytics company specializing in advanced optical technology and artificial intelligence for wound healing predictions. The company has developed the DeepView® Wound Imaging Solution, a proprietary multispectral imaging system that has received FDA Breakthrough Designation for its application in assessing burn wounds. This innovative technology enables clinicians to differentiate between non-healing and healing human tissue that is typically invisible to the naked eye. By providing 'Day One' healing assessments for conditions such as burn wounds and diabetic foot ulcers, Spectral AI aims to enhance the accuracy and speed of treatment decisions in the wound care sector.

Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative treatments for severe bacterial and fungal infections, as well as oncology. The company markets isavuconazole, an antifungal drug available in intravenous and oral forms, to treat invasive aspergillosis and mucormycosis. Additionally, Basilea offers ceftobiprole, an intravenous antibiotic for treating community and hospital-acquired pneumonia, and is conducting Phase III clinical trials for its use in acute bacterial skin and skin structure infections, as well as Staphylococcus aureus bacteremia. The company is also advancing several investigational therapies, including Derazantinib, a small molecule inhibitor for intrahepatic cholangiocarcinoma; BAL101553, a tumor checkpoint controller; and BAL3833, a panRAF/SRC kinase inhibitor. With operational subsidiaries in the United Kingdom and Germany, Basilea Pharmaceutica's products are available in multiple countries, including the United States and various European and non-European markets.

Cepheid is a molecular diagnostics company specializing in developing, manufacturing, and distributing accurate yet user-friendly molecular systems and tests. Its automated solutions streamline complex genetic testing procedures, enabling institutions of all sizes to perform sophisticated analyses for infectious diseases and cancer. Cepheid's focus lies in applications where timely, precise results are crucial, such as managing infectious diseases and cancer.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Spectral AI, Inc. is a predictive analytics company specializing in advanced optical technology and artificial intelligence for wound healing predictions. The company has developed the DeepView® Wound Imaging Solution, a proprietary multispectral imaging system that has received FDA Breakthrough Designation for its application in assessing burn wounds. This innovative technology enables clinicians to differentiate between non-healing and healing human tissue that is typically invisible to the naked eye. By providing 'Day One' healing assessments for conditions such as burn wounds and diabetic foot ulcers, Spectral AI aims to enhance the accuracy and speed of treatment decisions in the wound care sector.

Visby Medical, Inc. is a diagnostics company based in San Jose, California, specializing in the development of polymerase chain reaction (PCR)-based diagnostic tests for infectious diseases. Founded in 2008 and formerly known as Click Diagnostics Inc., the company focuses on creating single-use, handheld testing kits that provide instrument-free results for various health conditions, including respiratory infections and sexually transmitted diseases. Visby Medical aims to redefine the testing and treatment of illnesses through a human-centric, technology-driven approach, ensuring that diagnostic tools are not only highly accurate but also user-friendly. The company's services are utilized by governments, national NGOs, and private health providers, reflecting its commitment to making infectious disease testing more accessible and convenient for patients.

First Light Diagnostics Inc. is a medical diagnostics company focused on developing automated products for the rapid detection of pathogens responsible for healthcare-associated infections. Based in Chelmsford, Massachusetts, the company offers a benchtop MultiPath analyzer, which is designed for hospital clinical microbiology laboratories and can identify both resistant and sensitive strains of Staphylococcus aureus, as well as various toxins and viruses. Their innovative diagnostic solutions address the increasing demand for accurate and cost-effective testing, which has been shown to significantly reduce hospital infection rates. First Light's proprietary MultiPath detection technology combines the performance of advanced laboratory tests with enhanced affordability and user-friendliness. By providing antimicrobial susceptibility tests that deliver results within hours, the company enables healthcare professionals to administer appropriate antibiotic treatments quickly, ultimately saving lives, reducing healthcare costs, and improving antibiotic stewardship. First Light Diagnostics was incorporated in 2006 and was formerly known as First Light Biosciences Inc. before its name change in January 2019.

Vaxxas is a biotechnology company based in Brisbane, Australia, focused on developing a novel needle-free vaccination technology. Established in 2011, Vaxxas employs proprietary dry-coating technology that significantly reduces or eliminates the need for refrigeration during the storage and transportation of vaccines, thereby addressing logistical challenges associated with the cold chain. The company's innovative delivery system features an array of vaccine-coated micro projections that penetrate the outer layers of the skin when applied with a specialized applicator device. This method allows for the direct deposition of vaccines among a dense population of immune cells in the skin, potentially transforming the global delivery of vaccines.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focusing on the development of therapies for immune-mediated diseases. Established in 2010, the company specializes in creating immunotherapies utilizing human microbiome-derived bacteria. Its innovative platform includes a collection of defined bacterial consortia, proprietary assays for selecting effective strains, and extensive datasets from human interventional studies. Vedanta Biosciences also possesses capabilities for cGMP-compliant manufacturing, allowing for the production of live bacterial therapies in powder form. This enables healthcare providers to administer oral treatments aimed at addressing autoimmune and inflammatory diseases efficiently, potentially pioneering a new category of therapies based on the human microbiome.

Moderna, Inc. is a biotechnology company established in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapeutics and vaccines using messenger RNA (mRNA) technology, which provides instructions for cells to produce proteins essential for various biological functions. Moderna has a diverse pipeline, with numerous programs targeting infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. As of September 2024, it has 40 mRNA development candidates in clinical trials across multiple therapeutic areas. The company's mRNA technology gained significant recognition with the authorization of its COVID-19 vaccine in December 2020. Moderna maintains strategic alliances with various organizations, including major pharmaceutical companies and research institutions, to enhance its research and development efforts.

QuidelOrtho, established in 1979 and headquartered in San Diego, California, specializes in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company offers a wide range of point-of-care (POC) diagnostic tests, covering infectious diseases, reproductive and women's health, and other clinical areas. These tests are marketed under brands such as QuickVue, QuickVue+, and Quidel. QuidelOrtho's products are distributed through a network of national and regional distributors, as well as a direct sales force, primarily in North America, with a presence also in EMEA, China, and other countries. The company's portfolio includes tests for influenza, group A strep, respiratory syncytial virus, pregnancy, chlamydia, and other conditions, aiding clinicians and patients worldwide in informed decision-making.

Corning Incorporated, headquartered in Corning, New York, is a global leader in manufacturing glass, ceramics, and related materials. Established in 1851, the company operates across several segments, including Display Technologies, Optical Communications, Environmental Technologies, Specialty Materials, and Life Sciences. The Display Technologies segment produces glass substrates for organic light-emitting diodes and liquid crystal displays utilized in televisions and computers. In Optical Communications, Corning provides optical fibers, cables, and various hardware solutions for telecommunications networks. The Environmental Technologies segment focuses on emissions control products for the automotive sector, while Specialty Materials includes advanced formulations for glass and ceramics. The Life Sciences segment offers laboratory products, including consumables and pharmaceutical glass packaging. Corning also develops Gorilla Glass for mobile devices and collaborates with companies like Intel Corporation to enhance technology solutions. Through its diverse product offerings, Corning aims to meet evolving market demands and support innovation in dynamic industries.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

RxSight, Inc. is a medical technology company based in Aliso Viejo, California, focused on enhancing vision for patients after cataract surgery. It has developed the RxSight Light Adjustable Lens system, which includes the Light Adjustable Lens (LAL), a Light Delivery Device (LDD), and associated accessories. This innovative technology is the first of its kind to allow healthcare professionals to customize and optimize visual acuity post-surgery, enabling precise reshaping of the lens to meet individual patient needs. Additionally, the LAL features ActivShield technology, providing built-in UV protection. Established in 1997 and originally named Calhoun Vision, Inc., the company rebranded to RxSight, Inc. in 2017.

Vela Diagnostics Pte. Ltd. specializes in developing advanced tools for sample processing, including sample lysis, nucleic acid extraction, and polymerase chain reaction (PCR). The company has created a platform that enhances clinical, technical, and economic outcomes in diagnostics. Vela Diagnostics provides comprehensive profiling and analytics capabilities, which are essential for medical decision-making and the detection of various bacteria, viruses, and gene mutations. By equipping diagnostic laboratories with innovative solutions, Vela Diagnostics enables them to deliver accurate and relevant research and diagnostic results, ultimately supporting improved patient care.

Moderna, Inc. is a biotechnology company established in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapeutics and vaccines using messenger RNA (mRNA) technology, which provides instructions for cells to produce proteins essential for various biological functions. Moderna has a diverse pipeline, with numerous programs targeting infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. As of September 2024, it has 40 mRNA development candidates in clinical trials across multiple therapeutic areas. The company's mRNA technology gained significant recognition with the authorization of its COVID-19 vaccine in December 2020. Moderna maintains strategic alliances with various organizations, including major pharmaceutical companies and research institutions, to enhance its research and development efforts.

Emergent BioSolutions is a global life sciences company based in Gaithersburg, Maryland, founded in 1998. The organization focuses on developing, manufacturing, and delivering medical countermeasures aimed at addressing biological and chemical threats, as well as emerging infectious diseases. It operates through three segments: Commercial, Products, and Services. The Commercial segment is the primary source of revenue, featuring products such as NARCAN, which is designed to counteract opioid overdoses. By providing essential public health products to government agencies and healthcare providers, Emergent BioSolutions plays a crucial role in enhancing safety and health on a global scale.

Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company based in Boston, Massachusetts, specializing in the development and commercialization of innovative therapies derived from novel tetracycline chemistry. The company’s lead product, NUZYRA, is a broad-spectrum antibiotic administered in both oral and intravenous forms, targeting adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Another significant product, SEYSARA, is designed for the treatment of moderate to severe acne vulgaris. Paratek has received Qualified Infectious Disease Product designation from the U.S. Food and Drug Administration for its lead antibiotic, reflecting its commitment to addressing urgent public health threats, including antibiotic resistance. The company maintains various collaboration agreements, including partnerships with Zai Lab and Allergan, as well as research agreements with academic institutions and military organizations, to further its mission in combating infectious diseases and exploring additional therapeutic areas such as multiple sclerosis and systemic inflammatory diseases.

GenMark Diagnostics, Inc. is a molecular diagnostics company headquartered in Carlsbad, California, specializing in the development and commercialization of its proprietary eSensor electrochemical detection technology. The company’s flagship XT-8 System, which has received FDA 510(k) clearance, allows for the detection of up to 72 distinct biomarkers from a single sample, producing results within 30 minutes. This system supports a variety of molecular diagnostic tests using compact workstations and self-contained, disposable test cartridges. GenMark also offers diagnostic tests for its XT-8 System, including panels for respiratory viruses, cystic fibrosis, thrombophilia risk, warfarin sensitivity, and hepatitis C virus genotyping. The company is actively developing its next-generation platform, the AD-8 System, which aims to further streamline the testing process. GenMark sells its products through direct sales and specialized service organizations across the United States and Europe.

MediWound Ltd. is an integrated biopharmaceutical company based in Yavne, Israel, that specializes in developing, manufacturing, and commercializing innovative therapeutic products for severe burns and chronic wounds. Founded in 2000, the company is known for its flagship product, NexoBrid, which is an FDA-approved biopharmaceutical designed for the removal of eschar in adults with deep partial- and full-thickness thermal burns, offering a less invasive alternative to surgical interventions. MediWound also advances other product candidates, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic and hard-to-heal wounds, and MWPC003 for connective tissue disorders. The company aims to address significant unmet medical needs in these areas and improve patient outcomes.

Summit Therapeutics Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in the discovery, development, and commercialization of novel antibiotics aimed at treating serious infectious diseases. The company focuses on addressing Clostridium difficile infection (CDI) with its lead product candidate, ridinilazole, which is currently undergoing Phase III clinical trials. Additionally, Summit is developing the DDS-01 series to combat infections caused by Neisseria gonorrhoeae and the DDS-04 series targeting Enterobacteriaceae. With operations in the United States and Europe, Summit Therapeutics aims to establish new standards of care for patients while creating value for payors and healthcare providers. Founded in 2003, the company is committed to advancing innovative treatments for infectious diseases.

First Light Diagnostics Inc. is a medical diagnostics company focused on developing automated products for the rapid detection of pathogens responsible for healthcare-associated infections. Based in Chelmsford, Massachusetts, the company offers a benchtop MultiPath analyzer, which is designed for hospital clinical microbiology laboratories and can identify both resistant and sensitive strains of Staphylococcus aureus, as well as various toxins and viruses. Their innovative diagnostic solutions address the increasing demand for accurate and cost-effective testing, which has been shown to significantly reduce hospital infection rates. First Light's proprietary MultiPath detection technology combines the performance of advanced laboratory tests with enhanced affordability and user-friendliness. By providing antimicrobial susceptibility tests that deliver results within hours, the company enables healthcare professionals to administer appropriate antibiotic treatments quickly, ultimately saving lives, reducing healthcare costs, and improving antibiotic stewardship. First Light Diagnostics was incorporated in 2006 and was formerly known as First Light Biosciences Inc. before its name change in January 2019.

Qpex Biopharma is a San Diego-based biopharmaceutical company founded in 2018, focused on developing innovative therapies to address the growing challenge of antimicrobial resistance. The company specializes in creating a pipeline of antibiotic drugs aimed at treating infectious diseases in both inpatient and outpatient settings. With a strong emphasis on the discovery, development, and regulatory approval of anti-infective medicines, Qpex Biopharma leverages its expertise and experience in collaboration with public and private partnerships to meet critical medical needs. The company's mission is to provide effective solutions for healthcare professionals facing the complexities of resistant infections, thereby enhancing treatment options for patients.

BioFactura, Inc. is a biotechnology company based in Frederick, Maryland, focused on the development and manufacturing of high-value biosimilars, biodefense medical countermeasures, and novel drugs tailored to client specifications. Established in 2001, BioFactura utilizes its proprietary StableFast Biomanufacturing Platform, which allows for the rapid generation of stable cell lines, to enhance the efficiency and quality of biopharmaceutical production. This innovative platform is characterized by its chemically-defined, serum- and cholesterol-free production medium, modular expression vectors, and a proprietary growth supplement, enabling the development of clonal production cell lines capable of yielding significant quantities of product in a short timeframe. In addition to its core manufacturing capabilities, BioFactura offers a range of services including expression system development, purification process development, and custom analytical development, alongside research and consulting services.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

Altimmune, Inc. is a clinical stage biopharmaceutical company based in Gaithersburg, Maryland, specializing in the development of innovative treatments for liver disease, obesity, and vaccines. The company’s pipeline includes HepTcell, an immunotherapeutic candidate for chronic hepatitis B, which has successfully completed Phase I clinical trials. Altimmune also develops NasoShield, an intranasal anthrax vaccine, and NasoVAX, a recombinant intranasal vaccine. Additionally, the company is advancing AdCOVID, a single-dose intranasal vaccine for COVID-19. In the preclinical stage, Altimmune is working on ALT-801, a peptide-based dual GLP-1/glucagon receptor agonist for non-alcoholic steatohepatitis, as well as ALT-702, a tumor immunostimulant aimed at cancer treatment. The company employs proprietary technology for non-invasive intranasal delivery of its products and collaborates with institutions such as the University of Alabama at Birmingham to further its research initiatives.

Spectral AI, Inc. is a predictive analytics company specializing in advanced optical technology and artificial intelligence for wound healing predictions. The company has developed the DeepView® Wound Imaging Solution, a proprietary multispectral imaging system that has received FDA Breakthrough Designation for its application in assessing burn wounds. This innovative technology enables clinicians to differentiate between non-healing and healing human tissue that is typically invisible to the naked eye. By providing 'Day One' healing assessments for conditions such as burn wounds and diabetic foot ulcers, Spectral AI aims to enhance the accuracy and speed of treatment decisions in the wound care sector.

Integrated BioTherapeutics is a biotechnology company that focuses on discovering novel vaccines and therapeutics for emerging infectious diseases. Its antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines, and a variety of other product candidates for emerging viruses.

Summit Therapeutics Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in the discovery, development, and commercialization of novel antibiotics aimed at treating serious infectious diseases. The company focuses on addressing Clostridium difficile infection (CDI) with its lead product candidate, ridinilazole, which is currently undergoing Phase III clinical trials. Additionally, Summit is developing the DDS-01 series to combat infections caused by Neisseria gonorrhoeae and the DDS-04 series targeting Enterobacteriaceae. With operations in the United States and Europe, Summit Therapeutics aims to establish new standards of care for patients while creating value for payors and healthcare providers. Founded in 2003, the company is committed to advancing innovative treatments for infectious diseases.

Velico Medical, Inc. is a pre-clinical medical technology company based in Beverly, Massachusetts, focused on developing and commercializing innovative products for preparing and storing blood components, particularly platelets and plasma. The company offers FrontlineODP (On Demand Plasma), which enables blood centers to convert plasma into a dried powder format, eliminating the need for freezing. Additionally, Velico Medical provides FrontlinePPS (Platelet Protection System), a technology designed to protect platelets from deterioration during storage. By advancing these technologies, Velico Medical aims to enhance the efficacy of blood products and reduce preventable deaths related to bleeding. The company was formerly known as ZymeQuest and was incorporated in 1991.

Sanofi Pasteur SA is a prominent global developer and manufacturer of vaccines, headquartered in Lyon, France. The company specializes in producing vaccines for a wide range of bacterial and viral diseases, including pertussis, diphtheria, typhoid fever, poliomyelitis, influenza, and mumps. Established in 1990, Sanofi Pasteur has a significant international presence with production facilities located in France, the United States, Canada, China, Thailand, and Argentina. Formerly known as Aventis Pasteur S.A., the company adopted its current name in 2004 and operates as a subsidiary of Sanofi-Aventis, contributing to public health through its extensive vaccine portfolio.

Moderna, Inc. is a biotechnology company established in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapeutics and vaccines using messenger RNA (mRNA) technology, which provides instructions for cells to produce proteins essential for various biological functions. Moderna has a diverse pipeline, with numerous programs targeting infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. As of September 2024, it has 40 mRNA development candidates in clinical trials across multiple therapeutic areas. The company's mRNA technology gained significant recognition with the authorization of its COVID-19 vaccine in December 2020. Moderna maintains strategic alliances with various organizations, including major pharmaceutical companies and research institutions, to enhance its research and development efforts.

Soligenix, Inc., a late-stage biopharmaceutical company based in Princeton, New Jersey, focuses on developing and commercializing treatments for rare diseases and serious side effects of cancer therapies, where there is an unmet medical need. The company operates through two segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops therapies such as SGX301 for cutaneous T-cell lymphoma, SGX942 for oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone for gastrointestinal disorders. The Public Health Solutions segment works on biodefense vaccines and therapeutics, including RiVax, a ricin toxin vaccine, and SGX943, a therapeutic candidate for antibiotic-resistant and emerging infectious diseases.

Terumo, established in Tokyo nearly a century ago, is a global leader in medical technology, dedicated to "Contributing to Society through Healthcare". With over 25,000 employees worldwide, the company operates in more than 160 countries, providing innovative medical solutions. Terumo's extensive portfolio includes vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, and essential medical products for daily clinical practice. Its businesses span from cardiac and vascular devices, such as guidewires and catheters, to blood management systems and general hospital products like diabetes management solutions. Terumo's commitment to innovation and patient care drives its mission to be of value to patients, medical professionals, and society.

Spectral AI, Inc. is a predictive analytics company specializing in advanced optical technology and artificial intelligence for wound healing predictions. The company has developed the DeepView® Wound Imaging Solution, a proprietary multispectral imaging system that has received FDA Breakthrough Designation for its application in assessing burn wounds. This innovative technology enables clinicians to differentiate between non-healing and healing human tissue that is typically invisible to the naked eye. By providing 'Day One' healing assessments for conditions such as burn wounds and diabetic foot ulcers, Spectral AI aims to enhance the accuracy and speed of treatment decisions in the wound care sector.

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company based in New York, specializing in health security and infectious disease markets. Established in 1995, the company develops antiviral drugs targeting lethal pathogens, including variola virus, which causes smallpox. Its primary product, TPOXX, is an orally administered antiviral treatment specifically designed for human smallpox disease. SIGA is dedicated to creating modern biodefense countermeasures against high-priority viral threats, aiming to prevent and treat diseases such as Ebola, dengue, and Lassa fever. The company primarily generates revenue from the United States market.